DE69917866D1 - Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe - Google Patents
Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter WirkstoffabgabeInfo
- Publication number
- DE69917866D1 DE69917866D1 DE69917866T DE69917866T DE69917866D1 DE 69917866 D1 DE69917866 D1 DE 69917866D1 DE 69917866 T DE69917866 T DE 69917866T DE 69917866 T DE69917866 T DE 69917866T DE 69917866 D1 DE69917866 D1 DE 69917866D1
- Authority
- DE
- Germany
- Prior art keywords
- bupropion hydrochloride
- drug delivery
- tablets containing
- controlled drug
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US184096 | 1998-10-30 | ||
US09/184,096 US6033686A (en) | 1998-10-30 | 1998-10-30 | Controlled release tablet of bupropion hydrochloride |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69917866D1 true DE69917866D1 (de) | 2004-07-15 |
DE69917866T2 DE69917866T2 (de) | 2005-07-07 |
Family
ID=22675529
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69917866T Expired - Lifetime DE69917866T2 (de) | 1998-10-30 | 1999-10-07 | Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe |
DE69937650T Expired - Lifetime DE69937650T2 (de) | 1998-10-30 | 1999-10-07 | Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69937650T Expired - Lifetime DE69937650T2 (de) | 1998-10-30 | 1999-10-07 | Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe |
Country Status (5)
Country | Link |
---|---|
US (1) | US6033686A (de) |
EP (2) | EP1004298B1 (de) |
AT (1) | ATE268593T1 (de) |
DE (2) | DE69917866T2 (de) |
ES (2) | ES2222020T3 (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
US8545880B2 (en) * | 1999-02-26 | 2013-10-01 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
US20030044462A1 (en) * | 2001-08-20 | 2003-03-06 | Kali Laboratories, Inc. | Sustained release tablets containing bupropion hydrochloride |
US20030091634A1 (en) * | 2001-09-14 | 2003-05-15 | Pawan Seth | Delayed release tablet of venlafaxin |
US20030118647A1 (en) * | 2001-12-04 | 2003-06-26 | Pawan Seth | Extended release tablet of metformin |
ES2399880T3 (es) * | 2002-03-15 | 2013-04-04 | Cypress Bioscience, Inc. | Milnaciprán para el tratamiento del síndrome del intestino irritable |
IN192747B (de) * | 2002-04-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
US20040121010A1 (en) * | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
US20060003004A1 (en) * | 2002-10-25 | 2006-01-05 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
US20040086567A1 (en) * | 2002-10-30 | 2004-05-06 | Pawan Seth | Bioequivalent composition of itraconazole and a hydrophilic polymer |
US6893660B2 (en) * | 2002-11-21 | 2005-05-17 | Andrx Pharmaceuticals, Inc. | Stable pharmaceutical compositions without a stabilizer |
US20040228830A1 (en) * | 2003-01-28 | 2004-11-18 | Collegium Pharmaceutical, Inc. | Multiparticulate compositions of milnacipran for oral administration |
US20040162320A1 (en) * | 2003-02-14 | 2004-08-19 | Pawan Seth | Solid composition containing nisoldipine a mixture of polyethylene oxides and an antioxidant |
CA2522708C (en) | 2003-04-29 | 2013-05-28 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
PT1575565E (pt) * | 2003-08-08 | 2010-03-03 | Biovail Lab Int Srl | Comprimido de libertação modificada de cloridrato de bupropiona |
EP1523979A1 (de) * | 2003-10-13 | 2005-04-20 | Wyeth | Darreichungsform mit verlängerter Freisetzung |
WO2005049003A1 (en) * | 2003-11-21 | 2005-06-02 | Ranbaxy Laboratories Limited | Extended release dosage forms of bupropion hydrochloride |
US20060024362A1 (en) * | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
US8586085B2 (en) * | 2004-11-08 | 2013-11-19 | Biokey, Inc. | Methods and formulations for making pharmaceutical compositions containing bupropion |
US20060099262A1 (en) * | 2004-11-08 | 2006-05-11 | Biokey, Inc. | Methods and formulations for making controlled release oral dosage form |
KR100670798B1 (ko) | 2004-12-17 | 2007-01-17 | 한국전자통신연구원 | 데이터베이스 캐시 시스템 |
US7645802B2 (en) * | 2005-06-27 | 2010-01-12 | Biovail Laboratories International Srl. | Bupropion hydrobromide and therapeutic applications |
US7671094B2 (en) | 2005-06-27 | 2010-03-02 | Biovail Laboratories International S.R.L. | Bupropion hydrobromide and therapeutic applications |
EP1896002A4 (de) * | 2005-06-27 | 2009-11-25 | Biovail Lab Int Srl | Bupropionsalzformulierungen mit modifizierter freisetzung |
CN101370488B (zh) | 2005-11-22 | 2012-07-18 | 奥雷西根治疗公司 | 增加胰岛素敏感性的组合物 |
WO2007062228A1 (en) * | 2005-11-28 | 2007-05-31 | Orexigen Therapeutics, Inc. | Sustained-release formulation of zonisamide |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
US20080069891A1 (en) * | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
US8703191B2 (en) * | 2006-07-25 | 2014-04-22 | Intelgenx Corp. | Controlled-release pharmaceutical tablets |
US7674479B2 (en) * | 2006-07-25 | 2010-03-09 | Intelgenx Corp. | Sustained-release bupropion and bupropion/mecamylamine tablets |
WO2008023390A2 (en) * | 2006-08-21 | 2008-02-28 | Jubilant Organosys Limited | Modified release pharmaceutical composition of bupropion hydrochloride |
US8445018B2 (en) * | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
TWI504419B (zh) | 2006-11-09 | 2015-10-21 | Orexigen Therapeutics Inc | 層狀醫藥調配物 |
JP2010508997A (ja) * | 2006-11-09 | 2010-03-25 | オレキシジェン・セラピューティクス・インコーポレーテッド | 減量薬を投与するための方法 |
WO2008156749A1 (en) * | 2007-06-18 | 2008-12-24 | The General Hospital Corporation | Combination therapy for depression |
WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
CN102105140B (zh) * | 2008-07-02 | 2013-10-23 | 巴斯夫欧洲公司 | 涂覆片剂的方法 |
US10610528B2 (en) | 2009-12-08 | 2020-04-07 | Intelgenx Corp. | Solid oral film dosage forms and methods for making same |
US20110136815A1 (en) | 2009-12-08 | 2011-06-09 | Horst Zerbe | Solid oral film dosage forms and methods for making same |
RU2616496C2 (ru) * | 2010-01-11 | 2017-04-17 | Ориксиджен Терапьютикс, Инк. | Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты) |
DK2858640T3 (da) | 2012-06-06 | 2020-06-29 | Nalpropion Pharmaceuticals Llc | Sammensætning til anvendelse i en fremgangsmåde til behandling af overvægt og fedme hos patienter med høj cardiovaskulær risiko |
WO2015065547A1 (en) | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
WO2020225773A1 (en) | 2019-05-07 | 2020-11-12 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
US20220062200A1 (en) | 2019-05-07 | 2022-03-03 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8322007D0 (en) * | 1983-08-16 | 1983-09-21 | Wellcome Found | Pharmaceutical delivery system |
DE3586600T2 (de) * | 1984-02-10 | 1993-02-18 | Benzon Pharma As | Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend. |
US4769027A (en) * | 1984-08-15 | 1988-09-06 | Burroughs Wellcome Co. | Delivery system |
DE3485618D1 (de) * | 1984-08-17 | 1992-04-30 | Wellcome Found | Zusammensetzung zur kontrollierten abgabe eines wirkstoffes und ihre herstellung. |
GB9217295D0 (en) * | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
DE69425453T2 (de) * | 1993-04-23 | 2001-04-12 | Novartis Ag | Wirkstoffabgabevorrichtung mit gesteuerter Freigabe |
US5358970A (en) * | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
-
1998
- 1998-10-30 US US09/184,096 patent/US6033686A/en not_active Expired - Lifetime
-
1999
- 1999-10-07 EP EP99402455A patent/EP1004298B1/de not_active Expired - Lifetime
- 1999-10-07 ES ES99402455T patent/ES2222020T3/es not_active Expired - Lifetime
- 1999-10-07 ES ES02011246T patent/ES2295256T3/es not_active Expired - Lifetime
- 1999-10-07 DE DE69917866T patent/DE69917866T2/de not_active Expired - Lifetime
- 1999-10-07 EP EP02011246A patent/EP1232747B1/de not_active Expired - Lifetime
- 1999-10-07 DE DE69937650T patent/DE69937650T2/de not_active Expired - Lifetime
- 1999-10-07 AT AT99402455T patent/ATE268593T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2222020T3 (es) | 2005-01-16 |
EP1232747A2 (de) | 2002-08-21 |
DE69937650T2 (de) | 2008-07-17 |
EP1004298A3 (de) | 2000-06-14 |
EP1232747A3 (de) | 2003-01-29 |
US6033686A (en) | 2000-03-07 |
EP1004298A2 (de) | 2000-05-31 |
DE69937650D1 (de) | 2008-01-10 |
EP1004298B1 (de) | 2004-06-09 |
ATE268593T1 (de) | 2004-06-15 |
EP1232747B1 (de) | 2007-11-28 |
DE69917866T2 (de) | 2005-07-07 |
ES2295256T3 (es) | 2008-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69917866D1 (de) | Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe | |
MXPA03012041A (es) | Sistema de administracion controlada de farmacos de retencion gastrica. | |
ATE412437T1 (de) | Silber enthaltende zusammensetzungen, geräte und verfahren zu deren herstellung | |
AP2001002237A0 (en) | Hydrogel-driven drug dosage form. | |
MXPA05012637A (es) | Tableta de liberacion modificada del clorhidrato de bupropion. | |
YU35302A (sh) | Dozirani oblik leka sa inicijalnim hidrogelom | |
HK1039054A1 (en) | Controlled release tablet comprising a hypoglycemic drug and an antihyperglycemic drug. | |
MX350380B (es) | Formas de dosificacion solida de liberacion modificada en el orden de cero. | |
NO20016108D0 (no) | Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger | |
HUP0002935A2 (hu) | Gyomorban visszatartott, szabályozott hatóanyag kibocsátású mikrogömböcskék javított gyógyszeradagolás elősegítésére | |
WO2003028660A3 (en) | Drug delivery devices and methods | |
DK0868912T3 (da) | Anvendelse af redispergerbare polymerpulvere eller polymergranulater til coating af farmaceutiske eller agrokemiske applikationsformer | |
ATE287260T1 (de) | Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung | |
DE60205749D1 (de) | Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe | |
NO20005394D0 (no) | Legemiddelavleveringssammensetninger bestÕende av klebende mikrosfærer | |
CA2396152A1 (en) | Osmotic device within an osmotic device | |
WO2002024174A3 (en) | Sustained release composition containing clarithromycin | |
ATE391496T1 (de) | Geschmacksmaskierte pharmazeutische formulierungen | |
ES2196620T3 (es) | Formulacion de liberacion prolongada que contiene venlafaxina. | |
BG108516A (en) | Pharmaceutical formulation | |
DK1169032T3 (da) | Ketoprofen-mikrogranuler, fremgangsmåde til fremstilling deraf og farmaceutiske præparater | |
WO2003053413A3 (en) | Sustained-release compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: BIOVAIL LABORATORIES, INTERNATIONAL SPL (BLS), COL |